Table 1.
Cancers associated with SETD2 mutation
| Cancer type | Mutation % (total samples) | References |
|---|---|---|
| Clear cell renal cell carcinoma | 15.6% (418 samples) | The Cancer Genome Atlas 2013a |
| High-grade glioma | 15% (543 samples) | Fontebasso et al. 2013 |
| Uterine carcinosarcoma Uterine corpus endometrioid carcinoma |
13.6% (22 samples) 9% (240 samples) |
Jones et al. 2014 The Cancer Genome Atlas et al. 2013 |
| Acute lymphocytic leukemia | 12% (125 samples) 10% (94 samples) |
Zhang et al. 2012; Mar et al. 2014 |
| Bladder urothelial carcinoma | 10.2% (107 samples) 6% (50 samples) |
The Cancer Genome Atlas 2014b; Van Allen et al. 2014 |
| Desmoplastic melanoma Melanoma Cutaneous melanoma |
10% (20 samples) 8% (25 samples) 5.5% (91 samples) |
Berger et al. 2012 Shain et al. 2015 Berger et al. 2012; Hodis et al. 2012 |
| Lung adenocarcinoma | 9% (230 samples) 5.5% (182 samples) |
Imielinski et al. 2012; The Cancer Genome Atlas 2014c |
| Colorectal adenocarcinoma | 8.3% (72 samples) 6.1% (212 samples) |
The Cancer Genome Atlas 2012; Seshagiri et al. 2012 |
| Pancreatic adenocarcinoma | 8.3% (109 samples) | Witkiewicz et al. 2015 |
| Stomach adenocarcinoma | 7% (287 samples) | The Cancer Genome Atlas 2014a |
| Papillary renal cell carcinoma | 7.6% (157 samples) | The Cancer Genome Atlas et al. 2016 |
| Cutaneous squamous cell carcinoma | 6.9% (29 samples) | Li et al. 2015 |
Cancers are selected for which the mutation rate in CBioPortal (Cerami et al. 2012; Gao et al. 2013) exceeded 5% and a publication was available. Indicated mutation rate reflects published results. Additional cancers discussed in the text are also included.